



US009340614B2

(12) **United States Patent**  
**Zeller et al.**

(10) **Patent No.:** **US 9,340,614 B2**  
(45) **Date of Patent:** **\*May 17, 2016**

- (54) **ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME**
- (71) Applicant: **Labrys Biologics, Inc.**, Redwood City, CA (US)
- (72) Inventors: **Joerg Zeller**, Ann Arbor, MI (US); **Kristian T. Poulsen**, San Francisco, CA (US); **Yasmina Noubia Abdiche**, Mountain View, CA (US); **Jaume Pons**, San Bruno, CA (US); **Sierra Jones Collier**, Menlo Park, CA (US); **Arnon Rosenthal**, Woodside, CA (US)
- (73) Assignee: **LABRYS BIOLOGICS, INC.**, Redwood City, CA (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/841,479**

(22) Filed: **Aug. 31, 2015**

(65) **Prior Publication Data**

US 2015/0361173 A1 Dec. 17, 2015

**Related U.S. Application Data**

- (60) Continuation of application No. 14/719,015, filed on May 21, 2015, which is a continuation of application No. 14/251,925, filed on Apr. 14, 2014, now Pat. No. 9,115,194, which is a continuation of application No. 14/086,816, filed on Nov. 21, 2013, now Pat. No. 8,734,802, which is a continuation of application No. 13/870,871, filed on Apr. 25, 2013, now Pat. No. 8,597,649, which is a continuation of application No. 13/179,846, filed on Jul. 11, 2011, now Pat. No. 8,586,045, which is a division of application No. 12/093,638, filed as application No. PCT/IB2006/003181 on Nov. 2, 2006, now Pat. No. 8,007,794.

- (60) Provisional application No. 60/736,623, filed on Nov. 14, 2005.

(51) **Int. Cl.**

**A61K 39/395** (2006.01)  
**C12P 21/08** (2006.01)  
**C07K 16/00** (2006.01)  
**C07K 16/26** (2006.01)  
**C07K 16/18** (2006.01)  
**A61K 31/4045** (2006.01)  
**A61K 39/00** (2006.01)

(52) **U.S. Cl.**

CPC ..... **C07K 16/26** (2013.01); **A61K 31/4045** (2013.01); **A61K 39/3955** (2013.01); **C07K 16/18** (2013.01); **A61K 2039/505** (2013.01); **C07K 2316/96** (2013.01); **C07K 2317/21** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/34** (2013.01); **C07K 2317/52** (2013.01); **C07K 2317/55** (2013.01); **C07K 2317/56** (2013.01); **C07K 2317/565** (2013.01); **C07K 2317/71** (2013.01); **C07K 2317/76** (2013.01); **C07K 2317/92** (2013.01)

- (58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

|           |    |         |                       |
|-----------|----|---------|-----------------------|
| 4,816,567 | A  | 3/1989  | Cabilly et al.        |
| 5,116,964 | A  | 5/1992  | Capon et al.          |
| 5,500,362 | A  | 3/1996  | Robinson et al.       |
| 5,545,806 | A  | 8/1996  | Lonberg et al.        |
| 5,545,807 | A  | 8/1996  | Surani et al.         |
| 5,569,825 | A  | 10/1996 | Lonberg et al.        |
| 5,625,126 | A  | 4/1997  | Lonberg et al.        |
| 5,633,425 | A  | 5/1997  | Lonberg et al.        |
| 5,661,016 | A  | 8/1997  | Lonberg et al.        |
| 5,750,373 | A  | 5/1998  | Garrard et al.        |
| 5,821,337 | A  | 10/1998 | Carter et al.         |
| 5,851,556 | A  | 12/1998 | Breton et al.         |
| 5,935,586 | A  | 8/1999  | De Lacharriere et al. |
| 6,168,809 | B1 | 1/2001  | De Lacharriere et al. |
| 6,180,370 | B1 | 1/2001  | Queen et al.          |
| 6,313,097 | B1 | 11/2001 | Eberlein et al.       |
| 6,344,438 | B1 | 2/2002  | De Lacharriere et al. |
| 6,509,014 | B1 | 1/2003  | De Lacharriere et al. |
| 6,521,609 | B1 | 2/2003  | Doods et al.          |

(Continued)

#### FOREIGN PATENT DOCUMENTS

|    |         |   |        |
|----|---------|---|--------|
| CN | 1308676 | A | 8/2001 |
| CN | 1671711 | A | 9/2005 |

(Continued)

#### OTHER PUBLICATIONS

Adam, et al. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model. *Pain*. Jul. 2006;123(1-2):179-86. Epub Apr. 12, 2006.

Adwanikar, et al. Spinal CGRP1 receptors contribute to supraspinally organized pain behavior and pain-related sensitization of amygdala neurons. *Pain*. Nov. 2007;132(1-2):53-66. Epub Mar. 1, 2007.

Al-Lazikani, et al. Standard conformations for the canonical structures of immunoglobulins. *J Mol Biol*. Nov. 7, 1997;273(4):927-48.

Almagro, et al. Antibody engineering: humanization, affinity maturation, and selection technique. *Therapeutic Monoclonal Antibodies*, Chapter 13, pp. 311-334, 2009.

Amara, et al. Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. *Science*. Sep. 13, 1985;229(4718):1094-7.

Ambalavanar, et al. Deep tissue inflammation upregulates neuropeptides and evokes nociceptive behaviors which are modulated by a neuropeptide antagonist. *Pain*. Jan. 2006;120(1-2):53-68. Epub Dec. 13, 2005.

American Academy of Neurology. New Drugs Offer Hope for Migraine Prevention. Apr. 22, 2014.

(Continued)

*Primary Examiner* — Christine J Saoud

*Assistant Examiner* — Jon M Lockard

(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

**20 Claims, 16 Drawing Sheets**